Clinical Trial Update: Study of Axitinib for Downstaging Large Renal Tumors Not Primarily Suitable for Partial Nephrectomy (AXIPAN) [Phase 2]

View source ↗

Summary

Phase 2 AXIPAN trial of Axitinib for downstaging large renal tumors not suitable for partial nephrectomy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Axitinib (Axitinib)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: cT2a N0NxM0 Renal Tumor | Phase 2 | Status: COMPLETED